Alterations and Prediction of Functional Profiles of Gut Microbiota After Fecal Microbiota Transplantation for Iranian Recurrent
Clostridioides difficile infection
fecal microbiota transplantation
functional profiles
gut dysbiosis
gut microbiome
inflammatory bowel disease
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
09
2021
accepted:
28
12
2021
entrez:
13
1
2022
pubmed:
14
1
2022
medline:
14
1
2022
Statut:
epublish
Résumé
Fecal microbiota transplantation (FMT) has emerged for the therapeutic treatment of recurrent FMT was performed to eight IBD patients via colonoscopy. Profiles of gut microbiota from donors and recipients were investigated using 16S rRNA gene sequence analysis. Patients experienced no IBD flare-ups or other adverse effects, and all recovered to full health. Moreover, all rCDI patients lacked the Bacteroidetes present in donor samples. After FMT, the proportion of Bacteroidetes increased until a normal range was achieved. More specifically, the relative abundance of FMT leads to significant alterations of the community structure of gut bacteria in rCDI patients with IBD. The change in relative abundance of Proteobacteria and bacterial diversity indicated that FMT promotes recovery from intestinal permeability and inflammation in rCDI patients. Moreover, strong negative correlation between
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Fecal microbiota transplantation (FMT) has emerged for the therapeutic treatment of recurrent
PATIENTS AND METHODS
METHODS
FMT was performed to eight IBD patients via colonoscopy. Profiles of gut microbiota from donors and recipients were investigated using 16S rRNA gene sequence analysis.
RESULTS
RESULTS
Patients experienced no IBD flare-ups or other adverse effects, and all recovered to full health. Moreover, all rCDI patients lacked the Bacteroidetes present in donor samples. After FMT, the proportion of Bacteroidetes increased until a normal range was achieved. More specifically, the relative abundance of
CONCLUSION
CONCLUSIONS
FMT leads to significant alterations of the community structure of gut bacteria in rCDI patients with IBD. The change in relative abundance of Proteobacteria and bacterial diversity indicated that FMT promotes recovery from intestinal permeability and inflammation in rCDI patients. Moreover, strong negative correlation between
Identifiants
pubmed: 35023946
doi: 10.2147/JIR.S338212
pii: 338212
pmc: PMC8747792
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105-116Informations de copyright
© 2022 Azimirad et al.
Déclaration de conflit d'intérêts
No potential conflicts of interest are reported by the authors.
Références
Microbiome. 2015 Mar 30;3:10
pubmed: 25825673
Int J Colorectal Dis. 2016 May;31(5):1093-1094
pubmed: 26525055
Nat Genet. 2021 Feb;53(2):156-165
pubmed: 33462485
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499
pubmed: 23439232
Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):206-16
pubmed: 26956066
ISME J. 2012 Mar;6(3):610-8
pubmed: 22134646
Aliment Pharmacol Ther. 2015 Aug;42(4):470-6
pubmed: 26096320
Sci Rep. 2018 Jun 29;8(1):9822
pubmed: 29959351
PLoS One. 2016 Oct 5;11(10):e0163962
pubmed: 27706213
Front Microbiol. 2018 Apr 10;9:646
pubmed: 29692762
Pediatr Ann. 2014 Oct;43(10):417-20
pubmed: 25290132
Gut Microbes. 2019;10(6):676-687
pubmed: 30866714
Gastroenterology. 2020 Mar;158(4):930-946.e1
pubmed: 31812509
J Clin Gastroenterol. 2010 May-Jun;44(5):354-60
pubmed: 20048681
Emerg Microbes Infect. 2020 Dec;9(1):1432-1443
pubmed: 32520657
Clin Infect Dis. 2014 Feb;58(4):541-5
pubmed: 24368622
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
mBio. 2014 Jun 17;5(3):e00893-14
pubmed: 24939885
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Bioinformatics. 2010 Jun 1;26(11):1463-4
pubmed: 20395285
J Inflamm (Lond). 2012 Jan 12;9(1):1
pubmed: 22239975
Aliment Pharmacol Ther. 2015 Sep;42(6):741-52
pubmed: 26198180
J Infect. 2019 Jan;78(1):1-7
pubmed: 30336176
EBioMedicine. 2016 Nov;13:37-45
pubmed: 27720396
Microorganisms. 2020 Apr 18;8(4):
pubmed: 32325688
Front Microbiol. 2018 Nov 02;9:2622
pubmed: 30450088
Bioinformatics. 2017 Mar 1;33(5):782-783
pubmed: 28025202
Int J Mol Sci. 2020 Mar 11;21(6):
pubmed: 32168885
Nat Biotechnol. 2020 Jun;38(6):685-688
pubmed: 32483366
mBio. 2012 Oct 23;3(5):
pubmed: 23093385
F1000Res. 2019 May 23;8:726
pubmed: 31737256
J Nutr Biochem. 2013 Dec;24(12):2138-43
pubmed: 24183308
Clin J Gastroenterol. 2018 Feb;11(1):1-10
pubmed: 29285689
Gut Microbes. 2020 Nov 9;12(1):1810531
pubmed: 32893721
Gastroenterology. 2019 Apr;156(5):1440-1454.e2
pubmed: 30529583
mSystems. 2019 Oct 22;4(5):
pubmed: 31641046
Mol Psychiatry. 2020 May;25(5):1068-1079
pubmed: 30833676
J Inflamm Res. 2020 Sep 18;13:563-570
pubmed: 32982371
BMC Microbiol. 2021 Jan 28;21(1):36
pubmed: 33509087
Front Microbiol. 2016 Jan 12;6:1543
pubmed: 26793178
Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G310-9
pubmed: 24284963
J Infect Dis. 2016 Jul 15;214(2):173-81
pubmed: 26908752
Front Pharmacol. 2020 Sep 18;11:574533
pubmed: 33041818
Expert Rev Gastroenterol Hepatol. 2016 Oct;10(10):1145-1152
pubmed: 26907220
Microbiome. 2017 May 15;5(1):55
pubmed: 28506317
Case Rep Gastroenterol. 2018 Feb 21;12(1):76-84
pubmed: 29606940
Inflamm Bowel Dis. 2016 Oct;22(10):2402-9
pubmed: 27580384
Appl Environ Microbiol. 2007 Mar;73(5):1576-85
pubmed: 17220268
Aliment Pharmacol Ther. 2017 Aug;46(3):213-224
pubmed: 28612983
Am J Gastroenterol. 2008 Jan;103(1):162-9
pubmed: 17916108
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
Cell Host Microbe. 2014 Mar 12;15(3):382-392
pubmed: 24629344
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
Gut Microbes. 2013 Mar-Apr;4(2):125-35
pubmed: 23333862